Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Catholic University of Korea | OTHER |
| Kyungpook National University Hospital | OTHER |
| Keimyung University Dongsan Medical Center | OTHER |
| Korea University Anam Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study investigate the impact of comprehensive geriatric assessments using activity of daily living (ADL), instrumental activity of daily living (IADL), and Charlson's comorbidity index (CCI) on survival and toxicities in Korean patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Elderly patients with DLBCL | Elderly patients (age>=65 years) with DLBCL treated with R-CHOP chemotherapy |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Event-free survival | Event-free survival was defined as death, relapse from complete remission, progression during or after treatment, and discontinuation or changes of therapy during treatments | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | 5 years | |
| Progression-free survival | 5 years | |
| Cumulative incidence of grade 3/4 adverse events and premature treatment discontinuation |
| Measure | Description | Time Frame |
|---|---|---|
| Average received relative dose intensity | The dose intensity of each agent of R-CHOP chemotherapy was calculated by dividing the total received dose of the agent by the number of weeks of treatment. The relative dose intensity of each agents then was calculated by dividing the received dose intensity by the projected dose intensity for the agent. The sum of the relative dose intensities of the individual agents was divided by the number of agents in the R-CHOP to yield the average received relative dose intensity. In this study the average received relative dose intensity is calculated. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Elderly patients (≥ 65 years) with DLBCL treated with R-CHOP
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ho-Young Yhim, MD, PhD | Chonbuk National University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chonbuk National University Hospital | Jeonju | 561-712 | South Korea |
Not provided
| ID | Term |
|---|---|
| D016403 | Lymphoma, Large B-Cell, Diffuse |
| ID | Term |
|---|---|
| D016393 | Lymphoma, B-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| OTHER |
| Korea University Guro Hospital | OTHER |
| Kosin University Gospel Hospital | OTHER |
| Pusan National University Hospital | OTHER |
| Soonchunhyang University Hospital | OTHER |
| Ajou University School of Medicine | OTHER |
| Chonnam National University Hospital | OTHER |
Not provided
Not provided
Not provided
| 1 year |
| 6 months |
| D009369 |
| Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |